Study Details

Back to Search Results

Long Term Follow Up of Sub-retinal Transplantation of hESC derived RPE Cells in Stargardt Macular Dystrophy Patients

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT02445612

Astellas Study ID

The unique identification code given by the study sponsor.

7316-CL-0004

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

N/A

Follow Trial

Condition

Eye Disorder with Progressive Visual Loss

Phase

N/A

Age

18 years - N/A

Sex

Female & Male

Product

N/A

Type

A type of clinical study in which participants are identified as belonging to study groups and are assessed for biomedical or health outcomes. Participants may receive diagnostic, therapeutic, or other types of interventions, but the investigator does not assign participants to a specific interventions/treatment.

Observational

Trial Dates

Jul 2012 - Jun 2019

Masking

Not Available

Enrollment number

13

Long Term Follow Up to a Phase I/II, Open-Label, Multi-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (MA09-hRPE) Cells in Patients with Stargardt’s Macular Dystrophy (SMD)

Study summary

Study documents

Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for Long Term Follow Up of Sub-retinal Transplantation of hESC derived RPE Cells in Stargardt Macular Dystrophy Patients? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Bascom Palmer Eye Institute

Miami, United States, 33136

Jules Stein Eye Institute, UCLA School of Medicine

Los Angeles, United States, 90095

Wills Eye Institute-Mid Atlantic Retina

Philadelphia, United States, 19107

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo